Skip to content

Remote Ischemic Preconditioning in Neurological Death Organ Donors

Remote Ischemic Preconditioning in Neurological Death Organ Donors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01515072
Acronym
RIPNOD
Enrollment
321
Registered
2012-01-23
Start date
2011-07-31
Completion date
2015-04-30
Last updated
2018-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organ Transplantation

Keywords

Remote Ischemic Preconditioning, Brain death organ donors, Delayed graft function, Donor management, Pulsatile perfusion

Brief summary

The purpose of this study is to determine whether application of lower limb remote ischemic preconditioning (RIPC) after determination of brain death improves donor stability, organ quality, organ yield, and early post transplant clinical outcomes. Neurological death donors will be stratified into standard and extended criteria donors (SCD/ECD) and randomized in a 1:1 fashion to RIPC or No intervention. The primary outcome is the number of organs recovered per donor. Secondary outcomes include donor hemodynamic state, donor organ-specific function parameters, pulsatile perfusion parameters, number of organs transplanted per donor, recipient hospital free survival and delayed graft function of kidneys. The sample size is powered to detect a difference of 0.44 organs recovered.

Detailed description

Study Design and Participants The RIPNOD trial was conducted from July 2011 to July 2014 as a prospective randomized trial in two OPOs (in New Jersey and in Texas) in the U.S. The funding organization, institutional review boards and the physician committees of the two organ procurement organizations (OPOs) approved the study. Exemptions for consent from potential recipients and for a data and safety monitoring board were granted. Consent for research was obtained from the donor's next of kin by OPO staff unless a 'first-person' consent existed. The study population consisted of neurological death organ donors. Eligible donors were age \> 6 years, in whom death declaration was either imminent or completed, and organ recovery was not expected within 6 hours of enrollment. Donors with severe trauma to lower extremity or on sulfonylurea agents were excluded (Trial Protocol in Supplement). Procedures Randomization (1:1) to No RIPC or RIPC groups in standard and extended criteria donors (SCD and ECD) strata occurred based on a computer-generated random table of numbers. In Texas, field coordinators performed the randomization through a website and administered the intervention. In New Jersey, research staff performed all trial activities and randomized using opaque, sealed envelopes. Organ recovery teams were informed of the study and sometimes knew of the group assignment. The recipient care teams and recipients were not aware of the group assignment. The intervention consisted of four cycles of inflation of a tourniquet around mid-thigh to 250 mm Hg for 5 minutes followed by 5 minutes of deflation. The initial intervention occurred in the right thigh as early as possible after declaration of death. The second intervention occurred in the left thigh 24 hours after the initial intervention, or immediately before recovery, if this was earlier. Videoconferences between the two sites helped standardize the intervention before the trial commenced. All decisions regarding donor management, organ recovery, machine perfusion of kidneys, transplantation of organs and care after transplantation were independent of the research teams. Outcomes and Data Collection The primary outcome was the total number of organs recovered per donor. Secondary outcomes were number of organs transplanted per donor, and changes from baseline to terminal (before aortic cross clamp) in vasopressor support, serum lactate, creatinine clearance, left ventricular ejection fraction, serum troponins, partial pressure of arterial oxygen: fraction inspired oxygen (P:F) ratio, dynamic and static lung compliance, and perfusate flow and resistance in machine perfused kidneys, delayed graft function (DGF) in transplanted kidneys and six-month hospital free survival in all recipients. A score quantified vasopressor support.14 All laboratory tests were performed at donor hospitals. Cockcroft-Gault equation was used to calculate creatinine clearance.15 Donor hospital cardiologists estimated the ventricular ejection fraction in transthoracic echocardiograms. OPO policies dictated machine perfusion of kidneys; perfusion, occurred at a central location in each OPO. Delayed graft function was defined as dialysis in the first week after transplant. Six month hospital-free survival was defined as the number of days recipients survived following the initial discharge after the transplant. All donor data were obtained prospectively from OPO records. Data after transplantation were obtained from the Scientific Registry of Transplant Recipients (SRTR). The SRTR data system includes data on all donors, waitlist candidates, and transplant recipients in the United States, submitted by members of the Organ Procurement and Transplantation Network (OPTN). The Health Resources and Services Administration (HRSA), U.S. Department of Health and Human Services provides oversight to the activities of the OPTN and SRTR contractors. Sample Size A sample size of 150 donors in each arm was estimated to provide 80% power to detect a difference of 0.44 of an organ recovered and 0.48 of an organ transplanted per donor. The difference criterion was chosen based on published results achieved with hormonal resuscitation in organ donors. 6 Pooled standard deviations (organs recovered: 1.35; organs transplanted: 1.5) from data of two OPOs were used. Statistical Analyses Intention to treat principle was used in all analyses. Discrete descriptive data are reported as counts and percent and continuous data as means (sd) or medians (interquartile range). Continuous variables were compared using either t, or equivalent non-parametric tests. Categorical variables were compared using chi square tests. Multivariate modeling with backward elimination - linear ones to model RIPC on recovery and transplantation of all (0-8) and abdominal organs (0-5) per donor, and logistic ones to model recovery/transplantation of \> 1 thoracic organ per donor and DGF - was performed. Because only seven fewer thoracic organs were transplanted than recovered the model for organs transplanted was used to analyze both outcomes. Donor characteristics of age, sex, race, cause of death, BMI, comorbidities (hypertension, diabetes, alcohol use, and hepatitis C), treatments (insulin, diuretics and steroids) and laboratory parameters (serum creatinine and P:F ratio) and OPO site were predictor variables in organ yield models. Donor age or stratum, cold ischemia, number of human leukocyte antigen mismatches and recipients' characteristics of age, sex, race, BMI, diabetes, hypertension, etiology of renal failure, panel reactive antibody and OPO site were predictor variables in models of DGF. For linear regression models, adjusted R2 was computed and residuals were assessed for normality; the C statistic was used to assess goodness of the fit for logistic regression. Statistical significance was set at p\<0.05. Post Hoc Analyses Rates of acute rejection of kidney during the first six months were compared between the two groups using chi square tests. Kaplan-Meier estimates and log rank tests were used to compare unadjusted outcomes of graft and patient survival at 6, 12 and 24 months. In heart, lung and liver recipients, retransplantation or death was defined as graft loss. In all other organs graft loss was death-censored. Cox proportional hazards models were used to estimate the effect of RIPC on the adjusted hazard ratio for six-month graft loss after controlling for OPO site, donor age or stratum and sex, cold ischemia time, number of antigen mismatches, organ transplanted, and recipient age, sex, race, BMI, diabetes and hypertension.

Interventions

Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.

Sponsors

Health Resources and Services Administration (HRSA)
CollaboratorFED
The University of Texas Health Science Center at San Antonio
CollaboratorOTHER
Rutgers, The State University of New Jersey
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
6 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Neurological death donors in whom brain death determination is imminent 2. First person consent or next of kin consent for research 3. Donors \>=6 years of age 4. Organ recovery not expected within 6 hours of consent. 5. Both sexes and ethnicities.

Exclusion criteria

1. Donation after cardiac death donors (DCD) 2. Live organ donors 3. No first person consent and next of kin decline research consent 4. Donor Age \< 6 years 5. Lower extremity trauma or recent amputation 6. Tissue only donors

Design outcomes

Primary

MeasureTime frameDescription
Number of Organs Recovered Per DonorAt time of organ recovery, up to 1 dayNumber of organs recovered per organ donor

Secondary

MeasureTime frameDescription
Change in Vasopressor ScoreVasopressor score was determined before aortic cross clamp minus the value prior to the first intervention, an average of 19 hoursChanges in the following: Vasopressor usage, serum Lactate, Creatinine clearance, arterial oxygen pressure:fraction of inspired oxygen (P:F) ratios, Lung Compliance, Cardiac biomarkers, ejection fraction (EF) from 2-dimensional Echocardiogram. Here we will present data for the change in vasopressor use evaluated using a vasopressor score. A numerical score calculated for number and dose of Vasopressors in use. The score is calculated using the following formula (from Zuppa AF et. al.CRIT CARE MED 2004 Vol. 32 p 2318-2322): Vasopressor Score= (dopamine dose\[y=ug/kg/min x 1\]) + (dobutamine dose \[ug/kg/min\] x 1) + (epinephrine dose \[ug/kg/min\] x100) + (norepinephrine dose \[ug/kg/min\] x 100) + (phenylephrine dose \[ug/kg/min\] x 100). The range for our study was 0-4900 with higher doses indicating higher vasopressor use in the donor.
Change in Serum LactateSubjects will be followed from admission to explantation, an average of 4.5 daysChange in serum lactate levels (mg/dL) from before intervention to the final value
Change in Creatinine ClearanceSubjects will be followed from admission to explantation, an average of 4.5 daysChange in creatinine clearance (mL/min by Cockcroft-Gault method) from before intervention to terminal value
Change in P:F RatioSubjects will be followed from admission to explantation, an average of 4.5 daysChange in ratio of arterial oxygen pressure:fraction inspired oxygen ratio from before intervention to terminal value
Change in Dynamic ComplianceSubjects will be followed from admission to explantation, an average of 4.5 daysChange in dynamic compliance of the lung from before intervention to terminal value Cdyn = Dynamic compliance; Vt = tidal volume; PIP = Peak inspiratory pressure (the maximum pressure during inspiration); PEEP = Positive End Expiratory Pressure: Cdyn= Vt/PIP - PEEP
Number of Organs Transplanted Per DonorWithin 24 hours of organ recoveryNumber of organs transplanted from each organ donor
Pulsatile Perfusion FlowUp to 24 hours of machine perfusionPerfusate flow (mL/min) in machine perfused kidneys.
Six Month Hospital Free Survival of All Organ Recipients6 months post-transplantSix month hospital-free survival was defined as the number of days recipients survived following the initial discharge after the transplant.
Delayed Graft Function (DGF) of Kidney Recipients.7 days post-transplantDGF is defined as the need for dialysis within the first week post transplantation.
Pulsatile Perfusion ParametersUp to 24 hours of machine perfusionPerfusate resistance (mm Hg/mL/min) in machine perfused kidneys.
Change in TroponinsSubjects will be followed from admission to explantation, an average of 4.5 daysChange in serum troponin I (ng/mL) from before intervention to terminal value

Countries

United States

Participant flow

Recruitment details

The RIPNOD trial was conducted from July 2011 to July 2014 in two organ procurement organizations (OPO) in the U.S. Consent for research was obtained from donors next of kin by the OPO staff unless a 'first person' consent existed.

Participants by arm

ArmCount
No RIPC
The donors assigned to this group will receive standard of care of management of brain death donors in each organ procurement organization.
166
RIPC
The donors assigned to this group would receive two RIPC interventions. The first one would occur immediately after brain death declaration and consent for organ donation. The second one would occur immediately before commencement of organ recovery. At each occasion RIPC would be induced by 4 cycles of mid-thigh inflation of tourniquet for 5 min followed by deflation for 5 minutes. RIPC (Remote Ischemic Preconditioning): Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
155
Total321

Baseline characteristics

CharacteristicNo RIPCRIPCTotal
Age, Continuous44 years42 years43 years
Age, Customized
11-25
24 participants34 participants58 participants
Age, Customized
26-35
39 participants27 participants66 participants
Age, Customized
36-45
26 participants34 participants60 participants
Age, Customized
46-75
77 participants60 participants137 participants
Body Mass Index (BMI)
BMI < 30.0
126 participants104 participants230 participants
Body Mass Index (BMI)
BMI =/> 30.0
40 participants51 participants91 participants
Central Line Use
No
45 participants39 participants84 participants
Central Line Use
Yes
121 participants116 participants237 participants
Co-Morbidities
Diabetes: No
147 participants134 participants281 participants
Co-Morbidities
Diabetes: Yes
19 participants21 participants40 participants
Co-Morbidities
Hypertension: No
108 participants107 participants215 participants
Co-Morbidities
Hypertension: Yes
58 participants48 participants106 participants
Co-Morbidities
Past or Current Smoker:No
77 participants56 participants133 participants
Co-Morbidities
Past or Current Smoker:Yes
89 participants99 participants188 participants
Declaration of Death to Initial Intervention, Hours5.8 hours7.3 hours6.5 hours
Hepatitis C Antibody
No
159 participants139 participants298 participants
Hepatitis C Antibody
Yes
7 participants16 participants23 participants
Initial Intervention to Cross Clamp
Intervention to Cross Clamp: 24.1-39.5 hours
35 participants25 participants60 participants
Initial Intervention to Cross Clamp
Intervention to Cross Clamp: 5.9-24.0 hours
123 participants115 participants238 participants
Initial Intervention to Cross Clamp
Intervention to Cross Clamp: Data not available
8 participants15 participants23 participants
Insulin Infusion
Insulin Infusion: No
119 participants113 participants232 participants
Insulin Infusion
Insulin Infusion: Yes
47 participants42 participants89 participants
P:F ratio249.8 ratio244.0 ratio248 ratio
Race/Ethnicity, Customized
African-American
35 participants42 participants77 participants
Race/Ethnicity, Customized
Hispanic
30 participants38 participants68 participants
Race/Ethnicity, Customized
Other
4 participants1 participants5 participants
Race/Ethnicity, Customized
White
97 participants74 participants171 participants
Region of Enrollment
United States
166 participants155 participants321 participants
Serum Chemistry: Creatinine1.0 mg/dL1.1 mg/dL1.06 mg/dL
Serum Chemistry: Lactate1.5 mg/dL1.6 mg/dL1.6 mg/dL
Serum Chemistry: Troponin I0.28 ng/ml0.31 ng/ml0.29 ng/ml
Sex: Female, Male
Female
59 Participants62 Participants121 Participants
Sex: Female, Male
Male
107 Participants93 Participants200 Participants
Steroids Administered
Steroids Administered: No
41 participants33 participants74 participants
Steroids Administered
Steroids Administered: Yes
125 participants122 participants247 participants
Vasopressor Score100 units on a scale16.0 units on a scale37 units on a scale
Ventricular Ejection Fraction0.6 proportion ejection fraction0.59 proportion ejection fraction0.6 proportion ejection fraction

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
deaths
Total, all-cause mortality
— / —— / —— / —— / —— / —— / —
other
Total, other adverse events
0 / 2470 / 2350 / 4940 / 4580 / 1660 / 155
serious
Total, serious adverse events
45 / 24751 / 23581 / 49454 / 4588 / 16614 / 155

Outcome results

Primary

Number of Organs Recovered Per Donor

Number of organs recovered per organ donor

Time frame: At time of organ recovery, up to 1 day

Population: Subjects were organ donors enrolled in this multicenter study

ArmMeasureValue (MEAN)Dispersion
No RIPCNumber of Organs Recovered Per Donor3.79 organs recovered per donorStandard Deviation 1.73
RIPCNumber of Organs Recovered Per Donor3.60 organs recovered per donorStandard Deviation 1.84
Comparison: Sample Size and Power estimation: A sample size of at least 150 donors in each arm was estimated to provide 80% power to detect a difference of 0.44 of an organ recovered and 0.48 of an organ transplanted per donor. The difference criterion was chosen based on published results achieved with hormonal resuscitation in organ donors. 6 Pooled standard deviations (organs recovered: 1.35; organs transplanted: 1.5) from data of two OPOs were used.p-value: 0.3895% CI: [-0.37, 0.21]t-test, 2 sided
Secondary

Change in Creatinine Clearance

Change in creatinine clearance (mL/min by Cockcroft-Gault method) from before intervention to terminal value

Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days

Population: Donors in whom two serum creatinine values (one before intervention and another after the initial intervention) are available.

ArmMeasureValue (MEDIAN)
No RIPCChange in Creatinine Clearance0 mL/min
RIPCChange in Creatinine Clearance0 mL/min
p-value: 0.55Wilcoxon (Mann-Whitney)
Secondary

Change in Dynamic Compliance

Change in dynamic compliance of the lung from before intervention to terminal value Cdyn = Dynamic compliance; Vt = tidal volume; PIP = Peak inspiratory pressure (the maximum pressure during inspiration); PEEP = Positive End Expiratory Pressure: Cdyn= Vt/PIP - PEEP

Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days

ArmMeasureValue (MEDIAN)
No RIPCChange in Dynamic Compliance2.30 L/cm H20
RIPCChange in Dynamic Compliance1.20 L/cm H20
p-value: 0.48Wilcoxon (Mann-Whitney)
Secondary

Change in P:F Ratio

Change in ratio of arterial oxygen pressure:fraction inspired oxygen ratio from before intervention to terminal value

Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days

ArmMeasureValue (MEDIAN)
No RIPCChange in P:F Ratio6.5 ratio
RIPCChange in P:F Ratio0.05 ratio
p-value: 0.55Wilcoxon (Mann-Whitney)
Secondary

Change in Serum Lactate

Change in serum lactate levels (mg/dL) from before intervention to the final value

Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days

Population: Donors in whom at least two serum lactate levels (one before and one after the initial intervention) were available

ArmMeasureValue (MEDIAN)
No RIPCChange in Serum Lactate0.12 mg/dL
RIPCChange in Serum Lactate0.20 mg/dL
p-value: 0.86Wilcoxon (Mann-Whitney)
Secondary

Change in Troponins

Change in serum troponin I (ng/mL) from before intervention to terminal value

Time frame: Subjects will be followed from admission to explantation, an average of 4.5 days

Population: Only donors in whom two troponin I values (one before intervention and another after the initial intervention) were available were included in this analysis

ArmMeasureValue (MEDIAN)
No RIPCChange in Troponins-0.04 ng/mL
RIPCChange in Troponins-0.09 ng/mL
p-value: 0.04Wilcoxon (Mann-Whitney)
Secondary

Change in Vasopressor Score

Changes in the following: Vasopressor usage, serum Lactate, Creatinine clearance, arterial oxygen pressure:fraction of inspired oxygen (P:F) ratios, Lung Compliance, Cardiac biomarkers, ejection fraction (EF) from 2-dimensional Echocardiogram. Here we will present data for the change in vasopressor use evaluated using a vasopressor score. A numerical score calculated for number and dose of Vasopressors in use. The score is calculated using the following formula (from Zuppa AF et. al.CRIT CARE MED 2004 Vol. 32 p 2318-2322): Vasopressor Score= (dopamine dose\[y=ug/kg/min x 1\]) + (dobutamine dose \[ug/kg/min\] x 1) + (epinephrine dose \[ug/kg/min\] x100) + (norepinephrine dose \[ug/kg/min\] x 100) + (phenylephrine dose \[ug/kg/min\] x 100). The range for our study was 0-4900 with higher doses indicating higher vasopressor use in the donor.

Time frame: Vasopressor score was determined before aortic cross clamp minus the value prior to the first intervention, an average of 19 hours

Population: Donors in whom vasopressor agent and dose were described in the OPO records before intervention and prior to aortic cross clamp.

ArmMeasureValue (MEDIAN)
No RIPCChange in Vasopressor Score-15.60 units on a scale
RIPCChange in Vasopressor Score-6.00 units on a scale
p-value: 0.63Wilcoxon (Mann-Whitney)
Secondary

Delayed Graft Function (DGF) of Kidney Recipients.

DGF is defined as the need for dialysis within the first week post transplantation.

Time frame: 7 days post-transplant

Population: Kidney recipients of donors in each arm.

ArmMeasureGroupValue (NUMBER)
No RIPCDelayed Graft Function (DGF) of Kidney Recipients.DGF: Yes45 participants
No RIPCDelayed Graft Function (DGF) of Kidney Recipients.DGF: No202 participants
RIPCDelayed Graft Function (DGF) of Kidney Recipients.DGF: Yes51 participants
RIPCDelayed Graft Function (DGF) of Kidney Recipients.DGF: No184 participants
p-value: 0.0795% CI: [0.95, 2.76]Chi-squared
p-value: 0.36Chi-squared
Secondary

Number of Organs Transplanted Per Donor

Number of organs transplanted from each organ donor

Time frame: Within 24 hours of organ recovery

Population: Subjects were organ donors enrolled in this multicenter study

ArmMeasureValue (MEAN)Dispersion
No RIPCNumber of Organs Transplanted Per Donor3.41 Organs transplanted from each donorStandard Deviation 1.9
RIPCNumber of Organs Transplanted Per Donor3.31 Organs transplanted from each donorStandard Deviation 1.94
Comparison: Sample Size A sample size of at least 150 donors in each arm was estimated to provide 80% power to detect a difference of 0.44 of an organ recovered and 0.48 of an organ transplanted per donor. The difference criterion was chosen based on published results achieved with hormonal resuscitation in organ donors. 6 Pooled standard deviations (organs recovered: 1.35; organs transplanted: 1.5) from data of two OPOs were used.p-value: 0.795% CI: [-0.33, 0.26]t-test, 2 sided
Secondary

Pulsatile Perfusion Flow

Perfusate flow (mL/min) in machine perfused kidneys.

Time frame: Up to 24 hours of machine perfusion

ArmMeasureGroupValue (MEAN)Dispersion
No RIPCPulsatile Perfusion FlowFlow at 1 hour, mL/min98.58 mL/minStandard Deviation 32.41
No RIPCPulsatile Perfusion Flow4 hours105.28 mL/minStandard Deviation 23.75
No RIPCPulsatile Perfusion Flow8 hours117.98 mL/minStandard Deviation 28.86
No RIPCPulsatile Perfusion Flow12 hours115.19 mL/minStandard Deviation 20.07
RIPCPulsatile Perfusion Flow12 hours106.36 mL/minStandard Deviation 32.55
RIPCPulsatile Perfusion FlowFlow at 1 hour, mL/min89.42 mL/minStandard Deviation 38.31
RIPCPulsatile Perfusion Flow8 hours94.21 mL/minStandard Deviation 32.64
RIPCPulsatile Perfusion Flow4 hours104.03 mL/minStandard Deviation 40.66
p-value: 0.5395% CI: [-10.1, 19.5]Regression, Linear
Secondary

Pulsatile Perfusion Parameters

Perfusate resistance (mm Hg/mL/min) in machine perfused kidneys.

Time frame: Up to 24 hours of machine perfusion

ArmMeasureGroupValue (MEAN)Dispersion
No RIPCPulsatile Perfusion ParametersResistance at 1 hour, mL/min0.29 Resistance, mm Hg/mL/minStandard Deviation 0.12
No RIPCPulsatile Perfusion ParametersResistance at 4 hours, mL/min0.25 Resistance, mm Hg/mL/minStandard Deviation 0.1
No RIPCPulsatile Perfusion ParametersResistance at 8 hours, mL/min0.22 Resistance, mm Hg/mL/minStandard Deviation 0.09
No RIPCPulsatile Perfusion ParametersResistance at 12 hours, mL/min0.22 Resistance, mm Hg/mL/minStandard Deviation 0.08
RIPCPulsatile Perfusion ParametersResistance at 12 hours, mL/min0.29 Resistance, mm Hg/mL/minStandard Deviation 0.22
RIPCPulsatile Perfusion ParametersResistance at 1 hour, mL/min0.38 Resistance, mm Hg/mL/minStandard Deviation 0.3
RIPCPulsatile Perfusion ParametersResistance at 8 hours, mL/min0.33 Resistance, mm Hg/mL/minStandard Deviation 0.23
RIPCPulsatile Perfusion ParametersResistance at 4 hours, mL/min0.31 Resistance, mm Hg/mL/minStandard Deviation 0.23
p-value: 0.00695% CI: [0.03, 0.17]Regression, Linear
Secondary

Six Month Hospital Free Survival of All Organ Recipients

Six month hospital-free survival was defined as the number of days recipients survived following the initial discharge after the transplant.

Time frame: 6 months post-transplant

Population: Recipients of all organs from donors enrolled in the two arms

ArmMeasureValue (MEDIAN)
No RIPCSix Month Hospital Free Survival of All Organ Recipients172 days
RIPCSix Month Hospital Free Survival of All Organ Recipients171 days
p-value: 0.97Wilcoxon (Mann-Whitney)
Post Hoc

Acute Kidney Rejection

Diagnosis of rejection as documented in the recipient records in the Scientific Registry of Transplant Recipients (SRTR).

Time frame: 6 months after kidney transplantation

Population: This outcome was examined in recipients of in SRTR that received kidneys from donors in the RIPNOD trial

ArmMeasureGroupValue (NUMBER)
No RIPCAcute Kidney RejectionRejection: Yes17 participants
No RIPCAcute Kidney RejectionRejection: No230 participants
RIPCAcute Kidney RejectionRejection: Yes13 participants
RIPCAcute Kidney RejectionRejection: No222 participants
p-value: 0.5Fisher Exact
Post Hoc

Death-Censored Kidney Graft Survival at 6, 12 and 24 Months

kidney graft survival censored for death with functioning graft

Time frame: Kidney graft survival was monitored from transplant date until retransplantation or death up to 2 years as in SRTR data file October 2015

Population: Included were kidneys transplanted alone or with pancreas. All kidney grafts transplanted from donors in the RIPNOD trial and in whom recipient records are available in SRTR were included in this analysis. Kidney graft loss is defined as loss of functioning graft or retransplantation during the 24 months post-transplant.

ArmMeasureGroupValue (NUMBER)
No RIPCDeath-Censored Kidney Graft Survival at 6, 12 and 24 MonthsDeath censored kidney survival: 6 months94.2 percentage of participants
No RIPCDeath-Censored Kidney Graft Survival at 6, 12 and 24 Months12 months92.5 percentage of participants
No RIPCDeath-Censored Kidney Graft Survival at 6, 12 and 24 Months24 months87.4 percentage of participants
RIPCDeath-Censored Kidney Graft Survival at 6, 12 and 24 MonthsDeath censored kidney survival: 6 months99.1 percentage of participants
RIPCDeath-Censored Kidney Graft Survival at 6, 12 and 24 Months12 months96.8 percentage of participants
RIPCDeath-Censored Kidney Graft Survival at 6, 12 and 24 Months24 months96 percentage of participants
p-value: 0.0195% CI: [0.04, 0.9]Log Rank
Post Hoc

Graft Survival

Kaplan-Meier estimates of 6, 12 and 24 months survival of all grafts

Time frame: Graft survival was monitored from transplant date until retransplantation or death up to 2 years as in SRTR data file October 2015

Population: All grafts transplanted from donors in the RIPNOD trial and in whom recipient records are available in SRTR were included in this analysis. Graft loss is defined as retransplantation or death during the 24 months post-transplant.

ArmMeasureGroupValue (NUMBER)
No RIPCGraft Survival6 months graft survival91.3 percentage of all grafts
No RIPCGraft Survival12 months88.8 percentage of all grafts
No RIPCGraft Survival24 months82.2 percentage of all grafts
RIPCGraft Survival6 months graft survival94.6 percentage of all grafts
RIPCGraft Survival12 months92.2 percentage of all grafts
RIPCGraft Survival24 months87.8 percentage of all grafts
p-value: 0.03Log Rank
Post Hoc

Recipient Survival

Kaplan-Meier estimates of 6, 12 and 24 months survival of all recipients

Time frame: Recipient survival was monitored from transplant date until death up to 2 years as in SRTR data file October 2015

Population: All recipients of organs from donors in the RIPNOD trial and in whom recipient records are available in SRTR were included in this analysis

ArmMeasureGroupValue (NUMBER)
No RIPCRecipient SurvivalRecipient survival: 6 months92 percentage of participants
No RIPCRecipient Survival12 months90.0 percentage of participants
No RIPCRecipient Survival24 months84.4 percentage of participants
RIPCRecipient SurvivalRecipient survival: 6 months94.1 percentage of participants
RIPCRecipient Survival12 months91.5 percentage of participants
RIPCRecipient Survival24 months87.1 percentage of participants
p-value: 0.37Log Rank

Source: ClinicalTrials.gov · Data processed: Mar 15, 2026